Industries > Pharma > Global Women’s Healthcare Market Forecast 2017-2027

Global Women’s Healthcare Market Forecast 2017-2027

Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome

PUBLISHED: 14 July 2017
PAGES: 154
PRODUCT CODE: PHA0212

Clear
WOOCS 2.2.1
SKU: PHA0212 Categories: , , ,

The revenue of the women’s healthcare market in 2016 is estimated at $31.1bn and is expected to grow at a CAGR of 3.8% in the first half of the forecast period. Among various segments in the Women’s Healthcare market, the Postmenopausal Osteoporosis segment dominated the Global Women’s Healthcare market with a share of 36.99% in 2016.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 154-page report you will receive 96 charts – all unavailable elsewhere.

The 154-page report provides clear detailed insight into the women’s healthcare market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Women’s Healthcare market forecasts from 2017-2027

• This report also breaks down the revenue forecast and SWOT Analysis for the main submarkets:
• Postmenopausal Osteoporosis
• Hormonal Contraceptives
• Infertility
• Endometriosis
• Polycystic Ovary Syndrome

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• The US and Latin America
• Japan
• The UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Rest of the World

Global Women’s Healthcare Market Forecast 2017-2027

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval

• This report also discusses the drivers, challenges and trends that affect the global women’s healthcare market

• Our study discusses the selected leading companies that are the major players in the global women’s healthcare market
• Bayer
• Eli Lilly
• Merck & Co.
• Pfizer
• Sanofi
• Amgen
• Novo Nordisk
• AbbVie
• Bristol-Myers Squibb (BMS)

Visiongain’s study is intended for anyone requiring commercial analyses for the women’s healthcare market. You find data, trends and predictions.

Buy our report today Global Women’s Healthcare Market Forecast 2017-2027: Postmenopausal Osteoporosis, Hormonal Contraceptives, Menopause, Infertility, Endometriosis, Polycystic Ovary Syndrome.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Women’s Healthcare Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Women’s Healthcare Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories